228 related articles for article (PubMed ID: 30248341)
1. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
3. Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.
Wang Y; Shi C; Lu Y; Poulin EJ; Franklin JL; Coffey RJ
Am J Pathol; 2015 Apr; 185(4):1123-34. PubMed ID: 25794708
[TBL] [Abstract][Full Text] [Related]
4. Targeted mobilization of Lrig1
Wroblewski LE; Choi E; Petersen C; Delgado AG; Piazuelo MB; Romero-Gallo J; Lantz TL; Zavros Y; Coffey RJ; Goldenring JR; Zemper AE; Peek RM
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19652-19658. PubMed ID: 31488717
[No Abstract] [Full Text] [Related]
5. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
[TBL] [Abstract][Full Text] [Related]
7. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.
Lu L; Teixeira VH; Yuan Z; Graham TA; Endesfelder D; Kolluri K; Al-Juffali N; Hamilton N; Nicholson AG; Falzon M; Kschischo M; Swanton C; Wright NA; Carroll B; Watt FM; George JP; Jensen KB; Giangreco A; Janes SM
J Pathol; 2013 Mar; 229(4):608-20. PubMed ID: 23208928
[TBL] [Abstract][Full Text] [Related]
8. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
Wang Y; Poulin EJ; Coffey RJ
Br J Cancer; 2013 May; 108(9):1765-70. PubMed ID: 23558895
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
10. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O
Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
[TBL] [Abstract][Full Text] [Related]
12. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
13. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
[TBL] [Abstract][Full Text] [Related]
14. Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.
Li F; Ye ZQ; Guo DS; Yang WM
Oncol Rep; 2011 Aug; 26(2):439-46. PubMed ID: 21567105
[TBL] [Abstract][Full Text] [Related]
15. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
[TBL] [Abstract][Full Text] [Related]
16. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
[TBL] [Abstract][Full Text] [Related]
17. LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
[TBL] [Abstract][Full Text] [Related]
19. In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear.
Del Rio T; Nishitani AM; Yu WM; Goodrich LV
PLoS Genet; 2013; 9(9):e1003824. PubMed ID: 24086156
[TBL] [Abstract][Full Text] [Related]
20. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]